Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action.

Jordan, S C; Quartel, A W; Czer, L S; Admon, D; Chen, G; Fishbein, M C; Schwieger, J; Steiner, R W; Davis, C; Tyan, D B

Jordan, S C; Quartel, A W; Czer, L S; Admon, D; Chen, G; Fishbein, M C; Schwieger, J; Steiner, R W; Davis, C; Tyan, D B.

Affiliation

Jordan SC; Steven Spielberg Pediatric Research Center and Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA. sjordan@mailgate.csmc.edu

Transplantation ; 66(6): 800-5, 1998 Sep 27.

Article in En | MEDLINE | ID: mdl-9771846

Subject(s)

Graft Rejection/prevention & control; Heart Transplantation/immunology; Immunoglobulins, Intravenous/therapeutic use; Kidney Transplantation/immunology; Adult; Antibodies, Anti-Idiotypic/blood; Antibodies, Anti-Idiotypic/immunology; Antibody Formation/drug effects; Antibody Formation/immunology; Antibody Specificity; Dose-Response Relationship, Drug; Female; Graft Rejection/blood; Graft Rejection/immunology; HLA Antigens/immunology; Humans; Isoantibodies/blood; Isoantibodies/immunology; Male

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Heart Transplantation / Kidney Transplantation / Immunoglobulins, Intravenous / Graft Rejection Limits: Adult / Female / Humans / Male Language: En Journal: Transplantation Year: 1998 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links